A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

July 7, 2023

Primary Completion Date

February 17, 2025

Study Completion Date

February 16, 2026

Conditions
HIVHIV Infections
Interventions
DRUG

DTG/3TC

DTG/3TC FDC will be administered once daily.

Trial Locations (65)

161

GSK Investigational Site, Rome

1100

GSK Investigational Site, Vienna

1200

GSK Investigational Site, Brussels

4021

GSK Investigational Site, Linz

6020

GSK Investigational Site, Innsbruck

6202

GSK Investigational Site, Nice

8208

GSK Investigational Site, Sabadell

9000

GSK Investigational Site, Ghent

10149

GSK Investigational Site, Turin

10467

GSK Investigational Site, The Bronx

19002

GSK Investigational Site, Guadalajara

19104

GSK Investigational Site, Philadelphia

20005

GSK Investigational Site, Washington D.C.

20037

GSK Investigational Site, Washington D.C.

20142

GSK Investigational Site, Milan

23538

GSK Investigational Site, Lübeck

24501

GSK Investigational Site, Lynchburg

27401

GSK Investigational Site, Greensboro

28204

GSK Investigational Site, Charlotte

30033

GSK Investigational Site, Decatur

30625

GSK Investigational Site, Hanover

30912

GSK Investigational Site, Augusta

31201

GSK Investigational Site, Macon

33133

GSK Investigational Site, Miami

33407

GSK Investigational Site, West Palm Beach

34982

GSK Investigational Site, Ft. Pierce

41100

GSK Investigational Site, Modena

43614

GSK Investigational Site, Toledo

44304

GSK Investigational Site, Akron

45100

GSK Investigational Site, Orléans

48072

GSK Investigational Site, Berkley

48202

GSK Investigational Site, Detroit

50009

GSK Investigational Site, Zaragoza

53226

GSK Investigational Site, Milwaukee

59208

GSK Investigational Site, Tourcoing

64111

GSK Investigational Site, Kansas City

64460

GSK Investigational Site, Monterrey

68198

GSK Investigational Site, Omaha

75004

GSK Investigational Site, Paris

78705

GSK Investigational Site, Austin

79106

GSK Investigational Site, Freiburg im Breisgau

80336

GSK Investigational Site, München

85015

GSK Investigational Site, Phoenix

89106

GSK Investigational Site, Las Vegas

92262

GSK Investigational Site, Palm Springs

93301

GSK Investigational Site, Bakersfield

97070

GSK Investigational Site, García Gineres

97239

GSK Investigational Site, Portland

02043

GSK Investigational Site, Boston

28401-7684

GSK Investigational Site, Wilmington

H4A 3J1

GSK Investigational Site, Montreal

K1H 8L6

GSK Investigational Site, Ottawa

M5G 2N2

GSK Investigational Site, Toronto

H2L 1N9

GSK Investigational Site, Montreal

1105 AZ

GSK Investigational Site, Amsterdam

3079 DZ

GSK Investigational Site, Rotterdam

3584 CX

GSK Investigational Site, Utrecht

4099-001

GSK Investigational Site, Porto

4200-319

GSK Investigational Site, Porto

4434-502

GSK Investigational Site, Vila Nova de Gaia

08243

GSK Investigational Site, Manresa (Barcelona)

L7 8XP

GSK Investigational Site, Liverpool

SE1 9RT

GSK Investigational Site, London

SW7 2AZ

GSK Investigational Site, London

M8 5RB

GSK Investigational Site, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY